Trial Profile
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 09 Aug 2016 Status changed from active, no longer recruiting to completed.
- 12 May 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 14 May 2015 Planned End Date changed to 1 Aug 2016 as reported by ClinicalTrials.gov record.